About BridGene Biosciences
BridGene Biosciences is a company based in Sunnyvale (United States) founded in 2018 by Irene Yuan and Ping Cao. BridGene Biosciences has raised $78.5 million across 5 funding rounds from investors including HHS, Lapam Capital and D Yee Capital. The company has 25 employees as of December 31, 2022. BridGene Biosciences operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Sunnyvale, United States
- Employees 25 as on 31 Dec, 2022
- Founders Irene Yuan, Ping Cao
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$78.5 M (USD)
in 5 rounds
-
Latest Funding Round
$28 M (USD), Series B
Oct 16, 2025
-
Investors
HHS
& 8 more
-
Employee Count
25
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of BridGene Biosciences
BridGene Biosciences has successfully raised a total of $78.5M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $28 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BridGene Biosciences
BridGene Biosciences has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Lapam Capital and D Yee Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital services are offered to support entrepreneurial growth.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for BridGene Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BridGene Biosciences
Investment portfolio details for BridGene Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BridGene Biosciences
Detailed financials for BridGene Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bridgene Biosciences Comparisons
Peer comparison for BridGene Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BridGene Biosciences
BridGene Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
Detailed competitors of BridGene Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bridgene Biosciences
Complete news archive for BridGene Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BridGene Biosciences
BridGene Biosciences was founded in 2018.
BridGene Biosciences is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.
Ping Cao is the current CEO of BridGene Biosciences. They have also founded this company.
BridGene Biosciences is a funded company, having raised a total of $78.5M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at BridGene Biosciences is 25.
BridGene Biosciences was founded in 2018 in Sunnyvale, United States, as a biotechnology firm focused on oncology therapeutics. Small-molecule drugs targeting cancer are developed through the proprietary Chemoproteomics platform, IMTAC. This technology is employed to screen compounds against the full proteome in live cells, facilitating identification of candidates for difficult-to-drug targets implicated in disease progression. Operations center on advancing these discoveries toward clinical applications.
BridGene Biosciences's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
BridGene Biosciences has 9 investors. Key investors include HHS, Lapam Capital, D Yee Capital, Junson Capital, and Kaitai Capital.